LM
MDGL icon

Luminus Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Luminus Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-122,833
Closed -$11.2M – 116
2019
Q4 		$11.2M Buy
+122,833
New +$11.9M 0.47% 46

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Luminus Management's MDGL Position: Q1 2020 in Review

Luminus Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2020, closing a stake of 122,833 shares — an estimated $11.2M sold.

Luminus Management first reported a position in MDGL in Q4 2019 and held it in 1 quarter. The position peaked at $11.2M in Q4 2019. 109 funds tracked by Wall St. Rank hold MDGL as of Q1 2020.

  • Luminus Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Luminus Management sold 122,833 Madrigal Pharmaceuticals shares in Q1 2020, an estimated $11.2M.
  • Luminus Management first reported a position in Madrigal Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Luminus Management's Madrigal Pharmaceuticals position peaked at $11.2M in Q4 2019.
  • 109 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2020.

Based on Luminus Management's 13F filing for Q1 2020, filed 15 May 2020.